CONCLUSION
Based on the analysis of the collected data, it appears that IL-8 may
not be a suitable prognostic marker for the conversion from clinically
isolated syndrome (CIS) to multiple sclerosis (MS). Conversely, the
CXCL13 marker shows greater promise in this regard. We observed an
inclination towards higher CXCL13 levels in patients who transitioned
from CIS to relapsing-remitting MS (RRMS). These findings are consistent
with previously published studies that have highlighted the prognostic
significance of CXCL13 in patients with CIS.
Considering the evidence from our results and those of other studies, it
is conceivable that CXCL13 holds potential as an indicator of
inflammatory activity in individuals with MS, and its inclusion in
routine clinical practice should be contemplated. Nonetheless, these
findings should be validated through further investigation involving a
larger patient cohort.